Sambucus Canadensis Flower

Dosage for Sambucus Canadensis Flower extract is highly individualized and must be determined by an allergy specialist through a process of titration.

Diagnostic Dosing

For skin prick testing, a single drop of the extract (typically at a concentration of 1:10 or 1:20 w/v) is applied to the skin, followed by a puncture. For intradermal testing, 0.02 mL to 0.05 mL of a much more dilute solution (e.g., 1:1000 w/v) is injected into the dermis.

Immunotherapy Dosing

Immunotherapy follows a two-phase schedule:

1. 1Build-up Phase: Injections are given 1–3 times per week. The starting dose is usually 0.05 mL of a very dilute solution (e.g., 1:100,000 w/v). The dose is gradually increased over 3–6 months until the maintenance dose is reached.
2. 2Maintenance Phase: Once the effective dose is reached (often 0.5 mL of a 1:10 or 1:20 w/v solution), injections are spaced out to once every 2–4 weeks for a duration of 3–5 years.

Sambucus Canadensis Flower extract is generally considered safe for pediatric use in children over the age of 5, provided they can communicate symptoms of a systemic reaction. Dosing is similar to adult protocols but may be adjusted based on the child's weight and the severity of their allergic sensitivity. It is not typically recommended for very young children (under age 2) due to the difficulty of monitoring for anaphylaxis.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the proteins are not cleared by the kidneys in a manner that would lead to systemic toxicity.

Hepatic Impairment

No dosage adjustments are necessary for patients with liver disease.

Elderly Patients

Elderly patients require cautious dosing, particularly if they have underlying cardiovascular disease. The risk of using epinephrine (the treatment for a reaction to the extract) must be weighed against the benefits of the extract itself.

This medication is NEVER self-administered at home. It must be administered by a healthcare professional in a clinical setting equipped with emergency resuscitation equipment.

• Administration: Subcutaneous injection in the outer aspect of the upper arm.
• Observation: Patients MUST remain in the clinic for at least 30 minutes following an injection to monitor for signs of anaphylaxis.
• Storage: The extract must be kept refrigerated at 2°C to 8°C (36°F to 46°F). It should not be frozen.

If a dose in the immunotherapy schedule is missed, the next dose may need to be reduced depending on how much time has passed.

• 1 week late: Usually the same dose as the last injection.
• 2-4 weeks late: The dose may be reduced to the previous level in the build-up schedule.
• Over 4 weeks late: The clinician may need to restart the build-up phase from a much lower concentration.

An 'overdose' in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current tolerance level. Signs include:

• Rapid onset of hives (urticaria).
• Swelling of the throat or tongue.
• Wheezing or difficulty breathing.
• Drop in blood pressure (hypotension).

In the event of an overdose or systemic reaction, epinephrine (1:1000) is the primary treatment, followed by antihistamines and corticosteroids as needed.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most patients receiving Sambucus Canadensis Flower extract will experience some form of local reaction. These are generally not dangerous but indicate the immune system is responding to the allergen.

• Local Swelling (Wheal): A raised, itchy bump at the injection site that usually appears within minutes and subsides within a few hours.
• Redness (Erythema): A warm, red patch around the injection site.
• Itching (Pruritus): Intense itching at the site of administration.
• Delayed Local Reaction: Swelling that appears 6 to 24 hours after the injection, which may feel like a firm knot under the skin.

These side effects are more systemic in nature and require close monitoring:

• Generalized Hives: Itchy welts appearing on parts of the body other than the injection site.
• Nasal Congestion: Sneezing or a runny nose shortly after the injection.
• Mild Cough: A dry, irritating cough.
• Fatigue: Some patients report feeling unusually tired for the remainder of the day after an injection.

• Angioedema: Deep swelling under the skin, often around the eyes, lips, or hands.
• Lightheadedness: A feeling of faintness, often associated with a mild drop in blood pressure.
• Nausea: Feeling sick to the stomach or experiencing mild abdominal cramping.

> Warning: Stop taking Sambucus Canadensis Flower and call your doctor immediately if you experience any of these.

• Anaphylaxis: This is a life-threatening systemic allergic reaction. Symptoms include a sudden feeling of doom, difficulty swallowing, rapid pulse, and fainting. It is a medical emergency.
• Severe Bronchospasm: Sudden, intense wheezing and inability to catch one's breath, particularly in patients with a history of asthma.
• Laryngeal Edema: Swelling of the throat that blocks the airway.
• Hypotensive Shock: A dangerous drop in blood pressure leading to loss of consciousness.

There are no known long-term 'toxic' side effects of Sambucus Canadensis Flower extract, as it is a biological protein. However, the long-term 'effect' is the desired modification of the immune system. In rare cases, patients may develop persistent nodules at the injection site if aluminum-adsorbed extracts are used over many years. There is no evidence that allergenic extracts increase the risk of autoimmune diseases or cancer.

While Sambucus Canadensis Flower extract may not have a specific individual black box warning for the brand, the entire class of allergenic extracts carries a general warning regarding the risk of severe non-fatal and fatal systemic reactions.

Summary of Class Warning:

• Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis.
• They should only be administered by physicians who are exceptionally experienced in the treatment of systemic reactions and have the necessary equipment (epinephrine, oxygen, IV fluids).
• Patients with unstable asthma are at a significantly higher risk for fatal outcomes.
• Patients must be observed for at least 30 minutes post-injection.

Report any unusual symptoms to your healthcare provider.

Sambucus Canadensis Flower extract is a potent biological agent. Its use is restricted to diagnostic and therapeutic protocols managed by board-certified allergists. The most critical safety consideration is the prevention and management of anaphylaxis. Patients must be in stable health on the day of their injection; if a patient is experiencing an acute asthma flare or has a fever, the injection should be postponed.

No specific FDA black box warning exists for Sambucus Canadensis Flower as a standalone ingredient, but it falls under the general safety mandates for all allergenic extracts. These mandates require administration in a medical facility with immediate access to epinephrine and airway management tools. The risk of death from allergenic extracts is extremely low (approximately 1 in 2.5 million injections), but the risk is present and must be managed through strict adherence to safety protocols.

• Allergic Reactions / Anaphylaxis Risk: This is the primary risk. Patients with high degrees of sensitivity (determined by skin test results) require more cautious dosing schedules.
• Asthma Status: Patients with symptomatic or poorly controlled asthma are at the highest risk for severe systemic reactions. Lung function (Peak Flow or FEV1) should be assessed before administration if asthma is a concern.
• Cardiovascular Disease: Patients with significant heart disease may not tolerate the stress of a systemic reaction or the effects of the epinephrine required to treat it.
• Beta-Blocker Therapy: Patients taking beta-blockers may be resistant to the effects of epinephrine, making a systemic reaction much harder to treat.

Regular monitoring is essential for safety and efficacy:

• Pre-Injection Screening: Check for current symptoms, new medications, or recent illnesses.
• 30-Minute Post-Injection Observation: Mandatory for every single dose.
• Lung Function Tests: Periodic spirometry may be recommended for asthmatic patients.
• Skin Test Re-evaluation: Periodically repeating skin tests can help determine if the patient is becoming less sensitive over the course of immunotherapy.

Most patients can drive and operate machinery after the 30-minute observation period. However, if a patient feels lightheaded, fatigued, or experiences a systemic reaction, they should avoid these activities until they have fully recovered and been cleared by their doctor.

Alcohol should be avoided for several hours before and after an injection. Alcohol can increase peripheral vasodilation (widening of blood vessels), which may theoretically increase the rate of allergen absorption and the severity of a potential allergic reaction.

Immunotherapy is typically discontinued after 3 to 5 years of successful treatment. There is no 'withdrawal syndrome' associated with stopping Sambucus Canadensis Flower extract. However, stopping prematurely (before 2 years) often results in the return of allergic symptoms upon exposure to elderberry pollen.

> Important: Discuss all your medical conditions with your healthcare provider before starting Sambucus Canadensis Flower.

There are few absolute contraindications for drug combinations, but the following are generally avoided:

• Non-Selective Beta-Blockers (e.g., Propranolol): These drugs block the receptors that epinephrine acts upon. If a patient has a severe reaction to the Sambucus extract, epinephrine may fail to work, leading to a potentially fatal outcome.

• Selective Beta-Blockers (e.g., Atenolol, Metoprolol): While slightly safer than non-selective versions, they still pose a risk of reducing epinephrine's efficacy. Use with extreme caution.
• ACE Inhibitors (e.g., Lisinopril, Enalapril): These medications can interfere with the body's ability to degrade kinins, potentially increasing the severity of an anaphylactic reaction and increasing the risk of angioedema.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of epinephrine, leading to a dangerous spike in blood pressure if a reaction is treated.

• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can increase the cardiovascular effects of epinephrine used during a reaction.
• Antihistamines (e.g., Loratadine, Cetirizine): These do not cause a dangerous interaction, but they MUST be stopped 3–7 days before diagnostic skin testing, as they will suppress the wheal and flare response, leading to a false-negative result.

There are no direct interactions between Sambucus Canadensis Flower extract and specific foods. However, patients with 'Oral Allergy Syndrome' may find that eating certain fruits (like melons or peaches) during the peak elderberry pollen season increases their overall 'allergic load,' making them more sensitive to their injections.

• Elderberry Supplements (Syrups/Gummies): While these are made from the fruit and not the pollen, patients with severe pollen allergies should use caution, as some supplements may contain trace amounts of pollen proteins that could theoretically lower the threshold for a reaction to the clinical extract.
• St. John's Wort: May increase photosensitivity, but has no direct interaction with allergenic extracts.

• Skin Tests: As mentioned, antihistamines and certain sleep aids will interfere with the results.
• Total IgE/Specific IgE: Immunotherapy will eventually cause changes in these lab values (initially an increase, then a long-term decrease), but the extract does not 'interfere' with the testing process itself; it changes the underlying biology.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Sambucus Canadensis Flower extract must NEVER be used in the following circumstances:

• Severe, Uncontrolled Asthma: Patients with an FEV1 consistently below 70% of predicted values are at an unacceptably high risk of fatal bronchospasm during a reaction.
• Recent Myocardial Infarction (Heart Attack): Within the last 3–6 months. The risk of a systemic reaction or the use of epinephrine could trigger another cardiac event.
• History of Severe Anaphylaxis to this Specific Extract: If a patient has previously had a near-fatal reaction to Sambucus Canadensis pollen extract, further immunotherapy is usually contraindicated.
• Inability to Communicate: Patients who cannot report early symptoms of a reaction (e.g., very young children or those with severe cognitive impairment) should not receive the extract.

Conditions requiring careful risk-benefit analysis include:

• Autoimmune Diseases: There is a theoretical concern that stimulating the immune system could worsen conditions like Lupus or Rheumatoid Arthritis, though clinical evidence for this is weak.
• Malignancy: Patients undergoing active chemotherapy may have unpredictable immune responses.
• Pregnancy (Initiation): Immunotherapy should not be started during pregnancy, though it may be continued if the patient was already on a stable maintenance dose.

Patients allergic to Sambucus Canadensis Flower may also show sensitivity to:

• Other members of the Adoxaceae or Caprifoliaceae families (e.g., Honeysuckle).
• Certain other spring-blooming shrubs.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Sambucus Canadensis Flower.

Sambucus Canadensis Flower extract is generally classified in a category similar to FDA Category C.

• Risk Summary: There are no adequate and well-controlled studies in pregnant women. However, systemic reactions (anaphylaxis) during pregnancy are dangerous as they can cause fetal hypoxia (lack of oxygen).
• Clinical Practice: Allergists typically do not start new immunotherapy during pregnancy. If a woman becomes pregnant while on a stable maintenance dose, the treatment is usually continued at that dose (without further increases) because the risk of a reaction is low and the benefit of controlling allergy/asthma symptoms is high.

It is not known if the allergenic proteins from Sambucus Canadensis Flower extract pass into breast milk. However, since these are large proteins that are processed locally by the immune system, it is highly unlikely they would reach the milk in any significant or active form. Breastfeeding is generally considered safe for women receiving allergy shots.

• Approved Age: Generally used in children 5 years and older.
• Safety: Children are at the same risk for systemic reactions as adults. The primary concern is the child's ability to sit still for the injection and stay for the 30-minute observation period.
• Growth: There is no evidence that allergenic extracts affect growth or development.

• Cardiovascular Risk: Patients over 65 are more likely to have underlying heart disease or be taking medications like beta-blockers, which increase the risk profile of immunotherapy.
• Immune Senescence: Older adults may have a less robust response to immunotherapy, meaning it may be less effective at inducing tolerance.

No dosage adjustments are needed. The extract's components are biological proteins that do not rely on renal filtration for their primary activity or clearance.

No dosage adjustments are needed. The liver is not involved in the primary metabolism of subcutaneous allergenic extracts.

> Important: Special populations require individualized medical assessment.

Sambucus Canadensis Flower extract acts as an exogenous antigen. Upon subcutaneous injection, the allergens (primarily proteins and glycoproteins) are taken up by Dendritic Cells (antigen-presenting cells) in the dermis. These cells migrate to local lymph nodes and present the allergen fragments to T-lymphocytes.

In an allergic individual, this presentation normally favors a Th2 response, leading to B-cell production of IgE. Immunotherapy with Sambucus extract forces a 'class switch.' It induces the production of Regulatory T-cells (Tregs) that secrete IL-10 and TGF-beta. These cytokines signal B-cells to produce IgG4 instead of IgE. IgG4 acts as a 'blocking antibody,' intercepting the elderberry pollen allergens before they can reach the IgE bound to mast cells, thus preventing the release of histamine.

• Onset of Action: Diagnostic skin test results appear within 15–20 minutes. For immunotherapy, clinical improvement typically takes 6 to 12 months of consistent treatment.
• Duration of Effect: A completed 3-to-5-year course of immunotherapy can provide 5 to 10 years (or more) of symptom relief after the injections are stopped.
• Tolerance: The goal of the medication is to induce immunological tolerance, not pharmacological tolerance. Unlike opioids, you do not need more of the drug to get the same effect; rather, you need more to 'challenge' the immune system to stay desensitized.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Local) |

| Protein Binding | Minimal (acts on cell surfaces) |

| Half-life | Hours (for proteins); Years (for immune memory) |

| Tmax | 15-30 minutes (for local reaction) |

| Metabolism | Proteolysis by immune cells |

| Excretion | Normal protein turnover |

• Composition: A complex mixture of water-soluble proteins, glycoproteins, and polysaccharides derived from the pollen of Sambucus canadensis.
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for various allergenic fractions.
• Solubility: Highly soluble in aqueous buffers or 50% glycerin solutions.

Sambucus Canadensis Flower is a Non-Standardized Pollen Allergenic Extract. It belongs to the same therapeutic family as extracts for Ragweed, Timothy Grass, and Oak pollen. While it shares botanical origins with elderberry fruit extracts, its clinical use is strictly limited to immunology.